[Skip to Content]
[Skip to Content Landing]
March 1983

Methyldopa-Induced Immune Hemolytic Anemia and Chronic Active Hepatitis

Author Affiliations

From the Departments of Internal Medicine (Drs Shalev, Mosseri, and Stalnikowicz) and Pathology (Dr Ariel), Hadassah University Hospital, Mt Scopus, Jerusalem.

Arch Intern Med. 1983;143(3):592-593. doi:10.1001/archinte.1983.00350030206040

• Immune hemolytic anemia and chronic active hepatitis developed concurrently in a 76-year-old man after prolonged therapy with methyldopa. Both complications disappeared following cessation of treatment with the offending drug and a short course of a high-dose corticosteroid (prednisone). Inhibition of T-suppressor lymphocyte function by methyldopa may be instrumental in the emergence of autoimmune complications following usage of the drug.

(Arch Intern Med 1983;143:592-593)